Group items tagged

Community Pharmacy England (CPE) has expressed dissatisfaction with the spring budget as it brings "no specific relief" for the community pharmacy sector, which is grappling with "soaring costs and severe medicine supply and pricing issues." UK Chancellor Jeremy Hunt announced his Spring Budget on Wednesday, confirming an extra £2.5 billion in day-to-day revenue funding for the NHS in England in 2024-25 and a new NHS productivity plan worth £3.4bn to modernise IT systems. The Chancellor said that day-to-day spending would grow by 1 per cent per year on average in real terms, and the productivity plan is estimated to "unlock £35 billion worth of savings" from 2025-26 to 2029-30. However, CPE chief executive, Janet Morrison commented that the budget has "no obvious good news" for community pharmacies who need "urgent relief from the ongoing unsustainable funding and operational pressures" they are facing. Morrison described the investment in Pharmacy First as "the most significant investment in pharmacies in a decade", but emphasised the need for further support to stabilise the sector and its core contractual arrangements.

Recognising her remarkable contribution in the profession of pharmacy, Christine Gilmour, the Director of Pharmacy at NHS Lanarkshire, has been designated as a Fellow of the Royal Pharmaceutical Society (RPS). Christine, who joined NHS Lanarkshire as trust chief pharmacist for University Hospital Hairmyres and Stonehouse in 1994. She has been in her current role as Director of Pharmacy for 17 years now. Considered to be one of the highest accolades in the domain of pharmacy, this fellowship recognises the distinction of an RPS member in the pharmacy career. NHS Lanarkshire executive medical director, Dr Chris Deighan commented: "We are extremely proud of Christine. This is a fantastic achievement and recognises all the hard work, dedication and expertise Christine has displayed across her career."

Derriford Hospital is set to move its outpatient pharmacy to a bigger unit, which will be twice as big as the current size. The new pharmacy, due to open in Spring 2024, is located adjacent to the hospital's on-site Costa Coffee shop in the multistorey car park building. University Hospitals Plymouth NHS Trust said work is ongoing on the new 155 square metres pharmacy, but measures such as covered seating has been implemented. Additionally, the pharmacy's opening times would be extended during the weekends to benefit patients who are unable to attend during the week, the Trust said, noting that demand for its services has grown by 25 per cent. Kandarp Thakkar, Chief Pharmacist & Clinical Director of Medicines Optimisation, said the pharmacy serves thousands of outpatient appointments each week.

Professor Mahendra Patel OBE, CEO of the Oxford University Centre for Research Equity (CfRE), has been appointed as an independent expert member of the UK Pharmacy Professional Leadership Advisory Board. The newly established Board comprises nine independent expert members (IEMs) with outstanding leadership capabilities, who were appointed through open recruitment, ensuring a "broad, balanced, and diverse" representation. Sir Hugh Taylor KCB, the Independent Chair of the Board, and the UK Chief Pharmaceutical Officers (CPhOs) - Andrew Evans (Wales), Cathy Harrison (Northern Ireland), Alison Strath (Scotland), and David Webb (England) - announced the appointment of IEMs in an open letter to the UK pharmacy professions. "Bringing a wealth of experience and expertise, they will play a pivotal role in the Board's work to deliver an exciting vision through supporting a new and dynamic phase of collaboration," the CPhOs said. As the CEO of CfRE, Professor Patel spearheads efforts aimed at addressing inequalities in healthcare.

In a move towards greater diversity and inclusivity, the National Pharmacy Association (NPA) has welcomed three accomplished women to its board of key members. Aisling O'Brien, Sukhi Basra, and Sehar Shahid-who is the youngest member- have joined the board, marking a significant step in the organisation's commitment to equality and representation. The announcement, made on the occasion of the International Women's Day, by chief executive, Paul Rees MBE via X reflects the organisation's dedication to celebrating and empowering women in the pharmacy profession. Sukhi Basra, the inaugural female board member since last April, adds a valuable dimension to the NPA. With her role as a Community Pharmacy KCW committee member and her experience in clinical pharmacy spanning over 25 years, she brings a wealth of knowledge and a distinctive viewpoint.

Community Pharmacy England (CPE) highlighted the untapped potential of community pharmacies in the prevention and management of long-term conditions to Conservative MPs during an event last week. The roundtable discussion was attended by a select group of influential and supportive MPs alongside community pharmacy owners, the Chief Executive of Community Pharmacy England, the Director of NHS Services, and patient representative group Healthwatch. MPs in attendance included Steve Double, MP for St Austell and Newquay, who chaired the discussion; Will Quince MP, former Minister for Pharmacy, Derek Thomas MP, Sir Peter Bottomley and Peter Aldous MP. They talked about the current pressures and funding crisis in community pharmacy, exploring solutions on how this could be eased and the huge benefits that can be unlocked.

Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday announced that fluoroquinolone antibiotics must only be administered when no other antibiotics are appropriate for use. It elaborated that fluoroquinolones given systemically (by mouth, injection, or inhalation) should only be prescribed "when other recommended antibiotics have failed, will not work due to resistance, or are unsafe to use in an individual patient." Previous regulations on fluoroquinolones stated that this class of antibiotics should not be prescribed for mild to moderate or self-limiting infections, or non-bacterial conditions. Further restrictions have been introduced after receiving reports from patients who have experienced long-lasting or disabling reactions following use of fluoroquinolones, the MHRA revealed. Dr Alison Cave, MHRA Chief Safety Officer, said: "Patient safety is our top priority. We have listened to the experience of patients regarding long-lasting and potentially irreversible adverse reactions following use of fluoroquinolone antibiotics, in some cases prescribed for mild-to-moderate infections.